While combination antiretroviral treatment has made HIV a treatable condition, eradication of the infection has not yet been achieved. Treatment needs to be administered as a prolonged, possibly lifelong treatment. Long-term toxicity, difficulty in adhering to complex regimes, possible pharmacokinetics problems, and intrinsically limited potency are all factors favouring the selection of drug-resistant viral strains. The development of drug resistance is now a major cause for treatment failure.
EuResist aims to:
- integrate biomedical information from three large and expanding databases in different European countries collecting the required critical mass of historical and prospective data;
- develop and validate models for the effective prediction of responses to treatment based on HIV genotype and additional clinical information;
- make the prediction system available on the web for the optimisation of antiretroviral treatment.
For further information, please visit:
http://www.euresist.org
Project co-ordinator:
Informa S.r.l. (IT)
Partners:
- Informa S.r.l. (IT)
- Università degli Studi di Siena (IT)
- Karolinska Institutet (SE)
- Universitaetsklinikum Koeln (DE)
- IBM Israel - Science and technology LTD (IL)
- Max-Planck Gesellshaft zur Foerderung der Wissenshaften e.v. (DE)
- MTA KFKI Reszecske-ES Magfizikai KutatoIntezet (HU)
- Kingston University (UK)
Timetable: from 01/06 to 06/08
Total cost: 2.973.355
EC funding: 2.143.000
Instrument: STREP
Project Identifier: IST-2004-027173